Rahuld Ballal News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Rahuld ballal. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Rahuld Ballal Today - Breaking & Trending Today

Enliven Therapeutics, Inc. (NASDAQ:ELVN) Short Interest Up 9.7% in April

Enliven Therapeutics, Inc. (NASDAQ:ELVN – Get Free Report) was the recipient of a significant increase in short interest during the month of April. As of April 15th, there was short interest totalling 4,640,000 shares, an increase of 9.7% from the March 31st total of 4,230,000 shares. Based on an average trading volume of 247,800 shares, […] ....

Manish Patel , Rahuld Ballal , Enliven Therapeutics Company Profile , Mirae Asset Global Investments Co , Sg Americas Securities , China Universal Asset Management Co , Exchange Traded Concepts , Enliven Therapeutics Inc , Enliven Therapeutics , Get Free Report , Director Rahul , Universal Asset Management , Traded Concepts , Mirae Asset Global Investments , Asset Global Investments , Enliven Therapeutics Daily , Nasdaq Elvn ,

Enliven Therapeutics (NASDAQ:ELVN) Shares Down 3.9% Following Insider Selling

Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN – Get Free Report) were down 3.9% during trading on Monday after an insider sold shares in the company. The company traded as low as $18.64 and last traded at $18.64. Approximately 9,380 shares traded hands during trading, a decline of 94% from the average daily volume of 144,773 […] ....

Rahuld Ballal , Highvista Strategies , Northern Trust Corp , Blackrock Inc , Partners Vi Llc , Geode Capital Management , Enliven Therapeutics Inc , Enliven Therapeutics , Get Free Report , Director Rahul , Street Corp , Capital Management , Trust Corp , Enliven Therapeutics Daily , Nasdaq Elvn ,

Insider Selling: Enliven Therapeutics, Inc. (NASDAQ:ELVN) Director Sells $61,761.96 in Stock

Enliven Therapeutics, Inc. (NASDAQ:ELVN – Get Free Report) Director Rahul D. Ballal sold 3,237 shares of Enliven Therapeutics stock in a transaction that occurred on Monday, April 1st. The shares were sold at an average price of $19.08, for a total transaction of $61,761.96. Following the transaction, the director now directly owns 22,341 shares of […] ....

Rahuld Ballal , Enliven Therapeutics Inc , Ameritas Investment Partners Inc , China Universal Asset Management Co , Tower Research Capital , Royal Bank , Enliven Therapeutics , Get Free Report , Director Rahul , Research Capital , Investment Partners , China Universal Asset Management , Enliven Therapeutics Daily , Nasdaq Elvn , Insider Trading , Nsider Trades ,

Enliven Therapeutics, Inc. (NASDAQ:ELVN) Director Rahul D. Ballal Sells 3,237 Shares

Enliven Therapeutics, Inc. (NASDAQ:ELVN – Get Free Report) Director Rahul D. Ballal sold 3,237 shares of the stock in a transaction that occurred on Monday, April 1st. The shares were sold at an average price of $19.08, for a total transaction of $61,761.96. Following the completion of the transaction, the director now owns 22,341 shares […] ....

Rahuld Ballal , Royal Bank , Tower Research Capital , China Universal Asset Management Co , Securities Exchange Commission , Ameritas Investment Partners Inc , Enliven Therapeutics Inc , Enliven Therapeutics , Get Free Report , Director Rahul , Exchange Commission , Research Capital , Investment Partners , China Universal Asset Management , Enliven Therapeutics Daily , Nasdaq Elvn , Insider Trading , Nsider Trades ,

Rahul D. Ballal Sells 3,237 Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN) Stock

Rahul D. Ballal Sells 3,237 Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN) Stock
themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.

Rahuld Ballal , Charles Schwab Investment Management Inc , Group Plc , Mirae Asset Global Investments Co , Tower Research Capital , Deutsche Bank , Enliven Therapeutics Inc , Enliven Therapeutics , Get Free Report , Director Rahul , Asset Global Investments , General Group Plc , Research Capital , Charles Schwab Investment Management , Schwab Investment Management , Enliven Therapeutics Daily ,